| Current Price | $50.10 | Mkt Cap | $101.9B |
|---|---|---|---|
| Open | $49.40 | P/E Ratio | 12.71 |
| Prev. Close | $50.10 | Div. (Yield) | $2.28 (4.6%) |
| Daily Range | $48.93 - $50.18 | Volume | 12,806,403 |
| 52-Wk Range | $48.25 - $81.42 | Avg. Daily Vol. | 13,017,011 |
Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.
| Current Price | $50.10 | Mkt Cap | $101.9B |
|---|---|---|---|
| Open | $49.40 | P/E Ratio | 12.71 |
| Prev. Close | $50.10 | Div. (Yield) | $2.28 (4.6%) |
| Daily Range | $48.93 - $50.18 | Volume | 12,806,403 |
| 52-Wk Range | $48.25 - $81.42 | Avg. Daily Vol. | 13,017,011 |
The best Bull and Bear pitches based on recency and number of recommendations.
Extremely attractive valuation for a company with a strong existing set of drugs and upside in their pipeline
Strong pipeline and a culture that wants to innovate. Strong focus on patients. Leadership seems to struggle with launching products and being competitive out the door. Long term will either find BMY on strong footing or acquired.
Read the most recent pitches from players about BMY.
Recs
Craigs22
(49.92)
Submitted: 10/4/2021 12:15:19 AM :
Start Price:
$55.62
NYSE:BMY Score:
-16.02
Extremely attractive valuation for a company with a strong existing set of drugs and upside in their pipeline
Recs
asdfk123
(81.58)
Submitted: 9/30/2021 12:32:58 PM :
Start Price:
$40.31
NYSE:BMY Score:
-28.37
Added to position @$59.72 per share.
Recs
TMFkodyk123
(32.41)
Submitted: 9/7/2021 7:32:03 PM :
Start Price:
$60.01
NYSE:BMY Score:
-18.40
BMY's growth prospects are promising with anticoagulant blockbuster Eliquis and oncology blockbusters Revlimid and Opdivo. When combined with BMY's valuation, BMY is poised to beat the S&P 500 over the next 5-10 years.
Find the members with the highest scoring picks in BMY.
d3lta4ce (33.64) Score: +255.45
The Score Leader is the player with the highest score across all their picks in BMY.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| 3750399 | 50.48 | 2/17/2009 |
|
NS | $12.84 | +290.03% | +482.88% | +192.86 | 0 Comment | |
| KlownKollegeGrad | < 20 | 1/6/2012 |
|
1Y | $23.88 | +109.62% | +258.76% | +149.14 | 0 Comment | |
| GuruMF3 | 67.99 | 6/27/2016 |
|
5Y | $55.95 | -10.51% | +130.09% | +140.60 | 0 Comment | |
| Biotechnut | < 20 | 7/9/2012 |
|
5Y | $24.56 | +103.86% | +239.12% | +135.26 | 0 Comment | |
| GuruMF6 | 64.18 | 5/10/2016 |
|
5Y | $56.90 | -12.01% | +122.09% | +134.10 | 0 Comment | |
| GuruMF5 | 62.54 | 5/10/2016 |
|
5Y | $56.90 | -12.01% | +122.09% | +134.10 | 0 Comment | |
| GuruMF4 | 30.94 | 6/13/2016 |
|
3W | $57.34 | -12.69% | +119.82% | +132.51 | 0 Comment | |
| imobillc | < 20 | 8/29/2011 |
|
5Y | $20.03 | +149.91% | +282.20% | +132.29 | 0 Comment | |
| GrandeTeam | 25.63 | 11/16/2011 |
|
5Y | $21.56 | +132.16% | +263.99% | +131.83 | 0 Comment | |
| bclan13 | 64.56 | 9/30/2013 |
|
5Y | $33.77 | +48.23% | +174.12% | +125.89 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
